Cottler-Fox M, Klein H G
Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892.
Arch Pathol Lab Med. 1994 Apr;118(4):417-20.
Recombinant DNA technology has made more than a dozen human cytokines available to treat patients with hematologic and oncologic disorders. These small glycoproteins mediate cell growth and differentiation and regulate complex cellular networks by autocrine, paracrine, and endocrine mechanisms. Direct infusions of hematopoietic cytokines can decrease the requirement for transfusion in many patients with hematologic disorders and malignancies and permit more aggressive myelosuppressive therapy. Stimulation of blood donors with cytokines may enhance collection of a variety of transfusion components from granulocytes to peripheral blood progenitor cells. Using combinations of recombinant growth factors can effect ex vivo cell expansion and differentiation. Such cellular components are currently being studied in immunotherapy of cancer, in molecular approaches to inherited and acquired genetic abnormalities, and in bone marrow transplantation. In the future, this technology may be applied to producing transfusion components.
重组DNA技术已使十多种人类细胞因子可用于治疗血液学和肿瘤学疾病患者。这些小糖蛋白介导细胞生长和分化，并通过自分泌、旁分泌和内分泌机制调节复杂的细胞网络。直接输注造血细胞因子可减少许多血液学疾病和恶性肿瘤患者的输血需求，并允许进行更积极的骨髓抑制治疗。用细胞因子刺激献血者可能会增加从粒细胞到外周血祖细胞等多种输血成分的采集量。使用重组生长因子的组合可实现体外细胞扩增和分化。此类细胞成分目前正在癌症免疫治疗、遗传性和获得性基因异常的分子研究方法以及骨髓移植中进行研究。未来，这项技术可能会应用于生产输血成分。
